Abstract: Non-small cell lung cancer (NSCLC) has become one of the leading causes of death by cancer in the world. Research on the treatment of lung cancer has become a hot spot. The incidence of fibroblast growth factor receptor (FGFR) gene mutation and anaplastic lymphoma kinase gene fusion in NSCLC is low, and the curative effect of corresponding targeted drug treatment is not satisfactory. FGFR1 is a common abnormal gene in non-small cell lung cancer. Recent study gradually found its abnormal amplification in various tumors, and also found that various related molecular-targeting drugs have an inhibitory effect on the corresponding tumor. This paper reviews the expression of FGFR1 in non-small cell lung cancer, its relationship with the clinical characteristics of NSCLC, and current research progress in targeted drug therapy.